Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

DGAP-News: Abivax veranstaltet am 17. Februar 2022 ein Satellite Symposium auf dem 17. Kongress der European Crohn's and Colitis Organisation (ECCO)
DGAP-News: Abivax veranstaltet am 17. Februar 2022 ein Satellite Symposium auf dem 17. Kongress der European Crohn's and Colitis Organisation (ECCO)
DGAP-News: Abivax veranstaltet am 17. Februar 2022 ein Satellite Symposium auf dem 17. Kongress der European Crohn's and Colitis Organisation (ECCO)
eqs_de 
0 08.02.22
DGAP-News: Abivax to host Satellite Symposium at the 17th Congress of ECCO on Feb. 17, 2022
DGAP-News: Abivax to host Satellite Symposium at the 17th Congress of ECCO on Feb. 17, 2022
DGAP-News: Abivax to host Satellite Symposium at the 17th Congress of ECCO on Feb. 17, 2022
eqs_en 
0 08.02.22
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
eqs_en 
0 04.02.22
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
eqs_en 
0 03.02.22
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
eqs_en 
0 03.02.22
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
eqs_en 
0 03.02.22
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
eqs_en 
0 03.02.22
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
eqs_en 
0 03.02.22
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
eqs_en 
0 03.02.22
Lonza erzielt ein starkes Ergebnis in 2021 mit 20% Umsatzwachstum (kWk)
Lonza erzielt ein starkes Ergebnis in 2021 mit 20% Umsatzwachstum (kWk)
Lonza erzielt ein starkes Ergebnis in 2021 mit 20% Umsatzwachstum (kWk)
eqs_de 
0 26.01.22
Lonza Delivers Strong 2021 performance with 20% CER Sales Growth
Lonza Delivers Strong 2021 performance with 20% CER Sales Growth
Lonza Delivers Strong 2021 performance with 20% CER Sales Growth
eqs_en 
0 26.01.22
DGAP-News: Abivax Finanzkalender 2022
DGAP-News: Abivax Finanzkalender 2022
DGAP-News: Abivax Finanzkalender 2022
eqs_de 
0 25.01.22
DGAP-News: Abivax 2022 Financial Communication Calendar
DGAP-News: Abivax 2022 Financial Communication Calendar
DGAP-News: Abivax 2022 Financial Communication Calendar
eqs_en 
0 25.01.22
DGAP-News: Abivax's phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO GI Cancers Symposium 2022
DGAP-News: Abivax's phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO GI Cancers Symposium 2022
DGAP-News: Abivax's phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO GI Cancers Symposium 2022
eqs_en 
0 19.01.22
DGAP-News: Abivax präsentiert die Ergebnisse der klinischen Phase 1/2 Studie mit ABX196 zur Behandlung von Leberkrebs am 21. Januar auf dem ASCO GI Cancers Symposium 2022
DGAP-News: Abivax präsentiert die Ergebnisse der klinischen Phase 1/2 Studie mit ABX196 zur Behandlung von Leberkrebs am 21. Januar auf dem ASCO GI Cancers Symposium 2022
DGAP-News: Abivax präsentiert die Ergebnisse der klinischen Phase 1/2 Studie mit ABX196 zur Behandlung von Leberkrebs am 21. Januar auf dem ASCO GI Cancers Symposium 2022
eqs_de 
0 19.01.22
DGAP-News: Abivax receives EMA Scientific Advice supportive of moving ABX464 into phase 3 clinical testing in ulcerative colitis
DGAP-News: Abivax receives EMA Scientific Advice supportive of moving ABX464 into phase 3 clinical testing in ulcerative colitis
DGAP-News: Abivax receives EMA Scientific Advice supportive of moving ABX464 into phase 3 clinical testing in ulcerative colitis
eqs_en 
0 13.01.22
DGAP-News: Abivax: Ergebnis der wissenschaftlichen Beratungen der europ. Arzneimittelbehörde (EMA) unterstützt die Überführung von ABX464 in die klinische Phase-3-Testung zur Behandlung von Colitis ulcerosa
DGAP-News: Abivax: Ergebnis der wissenschaftlichen Beratungen der europ. Arzneimittelbehörde (EMA) unterstützt die Überführung von ABX464 in die klinische Phase-3-Testung zur Behandlung von Colitis ulcerosa
DGAP-News: Abivax: Ergebnis der wissenschaftlichen Beratungen der europ. Arzneimittelbehörde (EMA) unterstützt die Überführung von ABX464 in die klinische Phase-3-Testung zur Behandlung von Colitis ulcerosa
eqs_de 
0 13.01.22
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler unterzeichnet exklusiven Liefervertrag für Ytterbium-176
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler unterzeichnet exklusiven Liefervertrag für Ytterbium-176
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler unterzeichnet exklusiven Liefervertrag für Ytterbium-176
eqs_de 
0 10.01.22
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176
eqs_en 
0 10.01.22
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler unterzeichnet exklusiven Liefervertrag für Ytterbium-176
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler unterzeichnet exklusiven Liefervertrag für Ytterbium-176
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler unterzeichnet exklusiven Liefervertrag für Ytterbium-176
eqs_de 
0 10.01.22
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176
eqs_en 
0 10.01.22
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
eqs_en 
0 05.01.22
DGAP-News: MicroVision Announces Timing Change of Webcast on January 5, 2022
DGAP-News: MicroVision Announces Timing Change of Webcast on January 5, 2022
DGAP-News: MicroVision Announces Timing Change of Webcast on January 5, 2022
eqs_en 
0 05.01.22
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
eqs_en 
0 04.01.22
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler kauft argentinischen SPECT-Spezialisten
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler kauft argentinischen SPECT-Spezialisten
DGAP-Adhoc: ​​​​​​​Eckert & Ziegler kauft argentinischen SPECT-Spezialisten
eqs_de 
0 03.01.22